Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1289-1293

  Fung Tomc, Joan C ^a   Gradelski, Elizabeth ^a   Huczko, Elizabeth ^a   Dougherty, Thomas J ^a   Kessler, Robert E ^a   Bonner, Daniel P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE;

ANTIBIOTIC RESISTANCE; ARTICLE; CROSS RESISTANCE; DRUG PROTEIN BINDING; ENTEROBACTER CLOACAE; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0029991407     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1289     Document Type: Article

References (32)

1. Azemun, P., T. Stull, M. Roberts, and A. L. Smith. 1981. Rapid detection of chloramphenicol resistance in Haemophilus influenzae Antimicrob. Agents Chemother. 20:168-170.
2. Ballow, C. H., and J. J. Schentag. 1992. Trends in antibiotic utilization and bacterial resistance. Diagn. Microbiol. Infect Dis. 15:37S-42S.
3. Bristol-Myers Squibb. Data on file.
4. Büscher, K.-H., W. Cullman, W. Dick, and M. Stieglitz. 1987. Selection frequency of resistant variants by various β-lactam antibiotics in clinical Enterobacter cloacae isolates. Chemotherapy (Basel) 33:40-51.
5. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
6. Bush, K., S. K. Tanaka, D. P. Bonner, and R. B. Sykes. 1985. Resistance caused by decreased penetration of β-lactam antibiotics into Enterobacter cloacae. Antimicrob. Agents Chemother. 27:555-560.
7. Chow, J. W., M. J. Fine, D. M. Shlaes, J. P. Quinn, D. C. Hooper, M. P. Johnson, R. Ramphal, M. M. Wagener, D. K. Miyashiro, and V. L. Yu. 1991. Enterobacter bacteremia. clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 8:585-590.
8. Dworzack, D. L., M. P. Pugsley, C. C. Sanders, and E. A. Horowitz. 1987 Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur. J. Clin. Microbiol. 6:456-459.
9. Follath, F., E. Costa, A. Thommen, R. Frei, A. Burdeska, and J. Meyer. 1987. Clinical consequences of development of resistance to third generation cephalosporins. Eur. J. Clin. Microbiol. 6:446-500.
10. Fung-Tomc, J., T. J. Dougherty, F. J. DeOrio, V. Simich-Jacobson, and R. E. Kessler. 1989. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels Antimicrob Agents Chemother. 33:498-502.
11. Fung-Tomc, J. C., E. Gradelski, B. Kolek, B. Minassian, M. Pucci, R. E. Kessler, and D. P. Bonner. 1995. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2. Antimicrob Agents Chemother. 39:386-393.
12. Gootz, T. D., C. C. Sanders, and R. V. Goering. 1982. Resistance to cefamandole: derepression of β-lactamases by cefoxitin and mutation in Enterobacter cloacae. J. Infect. Dis. 146:34-42.
13. Gradelski, E., J. Fung-Tomc, E. Huczko, and R. E. Kessler. 1993. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J. Antimicrob. Chemother 32(Suppl. B):75-80.
14. Hancock, R. E. W., and F. Bellido. 1992. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J. Antimicrob. Chemother 29(Suppl. A):1-6
15. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. p. 474-502. Cold Spring Harbor Laboratory. Cold Spring Harbor, N Y
16. Hiraoka, M., S. Masuyoshi, and S. Mitsuhashi. 1988. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime. J. Antibiot. 41:86-93.
17. Kaneko, M., A. Yamaguchi, and T. Sawai. 1984. Purification and characterization of two kinds of porins from the Enterobacter cloacae outer membrane J. Bacteriol. 158:1179-1181
18. Lampe, M. F., B. J. Allan, B. H. Minshew, and J. C. Sherris. 1982. Mutational enzymatic resistance of Enterobacter species to beta-lactam antibiotics. Antimicrob. Agents Chemother. 21:655-660
19. Lee, E. H., M. H. Nicolas, M. D. Kitzis, G. Pialoux, E. Collatz, and L. Gutmann. 1991. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob. Agents Chemother. 35:1093-1098
20. Marchou, B., M. Michea-Hamzehpour, C. Lucain, and J.-C. Pechère. 1987. Development of β-lactam-resistant Enterobacter cloacae in mice. J. Infect. Dis. 156:369-373.
21. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
22. Neu, H. C., N.-X. Chin, and A. Novelli. 1988. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 32:1666-1675.
23. Nikaido, H., W. Liu, and E. V. Rosenberg. 1990. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob. Agents Chemother. 34:337-342
24. Pechère, J.-C. 1988. Emergence of resistance during β-lactam therapy of gram-negative infections. Drugs 35(Suppl. 2):22-28
25. Pechère, J.-C., and I. R. Vladoianu. 1992. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob. Chemother. 29:563-573.
26. Piddock, L. J. V., and D. J. Griggs. 1991. Selection and characterization of cefepime-resistant gram-negative bacteria. J. Antimicrob. Chemother 28: 669-676.
27. Piddock, L. J. V., and E. A. Traynor. 1991. β-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria. J. Antimicrob. Chemother. 28:209-219.
28. Quinn, J. P., C. A, DiVincenzo, and J. Foster. 1987. Emergence of resistance to ceftazidime during therapy for Enterobacter cloacae infection. J. Infect. Dis. 155:942-947.
29. Sanders, W. E., J. H. Tenney, and R. E. Kessler. Efficacy of cefepime in infections due to multiply resistant Enterobacter. Clin Infect. Dis., in press.
30. Sirot, D. L., F. W. Goldstein, D. J. Soussy, A. L. Courtieu, M. O. Husson, J. Lemozy, M. Meyran, C. Moral, R. Perez, C. Quentin-Noury, M. E. Reverdy, J. M. Scheftel, M. Rosembaum, and Y. Rezvani. 1992. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob. Agents Chemother 36:1677-1681.
31. Vuye, A., and J. Pijck. 1985. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrob. Agents Chemother 27: 574-577.
32. Zhanel, G. G., J. A. Karlowsky, M. H. Saunders, R. J. Davidson, D. J. Hoban, R. E. Hancock, I. McLeau, and L. E. Nicolle. 1995 Develpment of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrob. Agents Chemother. 39:489-495.